Linda Brewer1, David Williams2,3, Alan Moore2. 1. General and Geriatric Medicine, Beaumont Hospital, Dublin, Ireland. lindabrewer@physicians.ie. 2. General and Geriatric Medicine, Beaumont Hospital, Dublin, Ireland. 3. Geriatric Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Abstract
PURPOSE: The incidence of osteoporosis-related fractures will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population. METHODS: When prescribing for older patients the effectiveness profile of drugs needs to be balanced against their tolerability in individual patients. RESULTS: Currently we have good anti-fracture data to support the use of many available anti-resorptive and anabolic drugs including bisphosphonates, strontium ranelate and recombinant human parathyroid hormone. We also have evidence to demonstrate the importance of calcium and vitamin D repletion in these patients. However, in recent years our understanding of normal bone physiology and the mechanisms underlying the development of osteoporosis has significantly advanced and this has led to the development of new therapies. Novel agents, particularly denosumab, but also inhibitors of cathepsin K and anabolic agents that act on Wnt signalling, will increase the therapeutic options for clinicians in the coming years. CONCLUSION: This review discusses the evidence supporting the use of currently available treatment options for osteoporosis and potential future advances in drug therapy. Particular consideration should be given when prescribing for certain older patients who have issues with compliance or tolerance and also in those with co-morbidities or levels of frailty that may restrict the choice of therapy. Understanding the evidence for the benefit and possible harm of osteoporosis treatments is critical to appropriate management of this patient population.
PURPOSE: The incidence of osteoporosis-related fractures will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population. METHODS: When prescribing for older patients the effectiveness profile of drugs needs to be balanced against their tolerability in individual patients. RESULTS: Currently we have good anti-fracture data to support the use of many available anti-resorptive and anabolic drugs including bisphosphonates, strontium ranelate and recombinant humanparathyroid hormone. We also have evidence to demonstrate the importance of calcium and vitamin D repletion in these patients. However, in recent years our understanding of normal bone physiology and the mechanisms underlying the development of osteoporosis has significantly advanced and this has led to the development of new therapies. Novel agents, particularly denosumab, but also inhibitors of cathepsin K and anabolic agents that act on Wnt signalling, will increase the therapeutic options for clinicians in the coming years. CONCLUSION: This review discusses the evidence supporting the use of currently available treatment options for osteoporosis and potential future advances in drug therapy. Particular consideration should be given when prescribing for certain older patients who have issues with compliance or tolerance and also in those with co-morbidities or levels of frailty that may restrict the choice of therapy. Understanding the evidence for the benefit and possible harm of osteoporosis treatments is critical to appropriate management of this patient population.
Authors: Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty Journal: J Bone Miner Res Date: 2009-04 Impact factor: 6.741
Authors: Areef Ishani; Terri Blackwell; Sophie A Jamal; Steven R Cummings; Kristine E Ensrud Journal: J Am Soc Nephrol Date: 2008-04-09 Impact factor: 10.121
Authors: John L Vahle; Masahiko Sato; Gerald G Long; Jamie K Young; Paul C Francis; Jeffery A Engelhardt; Michael S Westmore; Yanfei Linda; James B Nold Journal: Toxicol Pathol Date: 2002 May-Jun Impact factor: 1.902
Authors: Taishiro Kishimoto; Marc De Hert; Harold E Carlson; Peter Manu; Christoph U Correll Journal: Curr Opin Psychiatry Date: 2012-09 Impact factor: 4.741
Authors: A Reymondier; P Caillet; F Abbas-Chorfa; V Ambrosi; S B Jaglal; R Chapurlat; A-M Schott Journal: Osteoporos Int Date: 2012-05-16 Impact factor: 4.507
Authors: B J Smith; J L Graef; T J Wronski; E Rendina; A A Williams; K A Clark; S L Clarke; E A Lucas; B P Halloran Journal: Calcif Tissue Int Date: 2013-12-20 Impact factor: 4.333